LOGIN  |  REGISTER
Terns Pharmaceuticals
Astria Therapeutics

Tenet Healthcare Completes Sale of Six Hospitals in California

April 01, 2024 | Last Trade: US$128.89 0.83 -0.64

DALLAS / Apr 01, 2024 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) today announced that it has completed the sale of six hospitals and related operations in California consistent with previously disclosed terms.

Tenet completed the sale of its four Orange County and Los Angeles County hospitals and related operations to UCI Health – consistent with the approval of the University of California Board of Regents. The completed transaction includes Fountain Valley Regional Hospital, Lakewood Regional Medical Center, Los Alamitos Medical Center, Placentia-Linda Hospital, and related operations.

Tenet completed the sale of its two San Luis Obispo hospitals and related operations to Adventist Health. The completed transaction includes Sierra Vista Regional Medical Center, Twin Cities Community Hospital, and related operations.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Viking Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB